Abstract
Several imaging modalities including computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, optical imaging, and gamma scintigraphy have been used to diagnose cancer. Although CT and MRI provide considerable anatomic information about the location and the extent of tumors, they do not adequately differentiate residual or recurrent tumors from edema, radiation necrosis, or gliosis. Ultrasound images provide information about local and regional morphology with blood flow. Although optical imaging showed promising results, its ability to detect deep tissue penetration was not well demonstrated. Radionuclide imaging modalities such as positron emission tomography (PET) and single photon emission computed tomography (SPECT) are diagnostic cross-sectional imaging techniques that map the location and concentration of radionuclide-labeled compounds (Bar-Shalom et al. Semin Nucl Med 30:150–185, 2000; Plowman et al. Br J Neurosurg 11:525–532, 1997; Weber et al. Strahlenther Onkol 175:356, 1999). Beyond showing precisely where a tumor is and its size, shape, and viability, PET and SPECT are making it possible to “see” the molecular makeup of the tumor and its metabolic activity. Whereas PET and SPECT can provide a very accurate picture of metabolically active areas, their ability to show anatomic features is limited. As a result, new imaging modalities have begun to combine PET and SPECT images with CT scans for treatment planning. PET/CT and SPECT/CT scanners combine anatomic and functional images taken during a single procedure without having to reposition the patient between scans. To improve the diagnosis, prognosis, planning, and monitoring of cancer treatment, characterization of tumor tissue is extensively determined by development of more tumor-specific pharmaceuticals. Radiolabeled ligands as well as radiolabeled antibodies have opened a new era in scintigraphic detection of tumors and have undergone extensive preclinical development and evaluation.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bar-Shalom R, Valdivia AY, Blaufox MD. PET imaging in oncology. Semin Nucl Med. 2000;30:150–85.
Plowman PN, Saunders CA, Maisey M. On the usefulness of brain PET scanning to the paediatric neuro-oncologist. Br J Neurosurg. 1997;11:525–32.
Weber WA, Avril N, Schwaiger M. Relevance of positron emission tomography (PET) in oncology. Strahlenther Onkol. 1999;175:356.
Lau CL, Harpole DH, Patz E. Staging techniques for lung cancer. Chest Surg Clin North Am. 2000;10(4): 781–801.
Schulte M, Brecht-Krauss D, Heymer B, et al. Grading of tumors and tumor like lesions of bone: evaluation by FDG PET. J Nucl Med. 2000;41(10):1695–701.
Yutani K, Shiba E, Kusuoka H, et al. Comparison of FDG-PET with MIBI-SPECT in the detection of breast cancer and axillary lymph node metastasis. J Comput Assist Tomogr. 2000;24(2):274–80.
Franzius C, Sciuk J, Daldrup-Link HE, et al. FDG-PET for detection of osseous metastases from malignant primary bone tumors: comparison with bone scintigraphy. Eur J Nucl Med. 2000;27(9):1305–11.
Folpe AL, Lyles RH, Sprouse JT, et al. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res. 2000;6(4):1279–87.
Meyer PT, Spetzger U, Mueller HD, et al. High F-18 FDG uptake in a low-grade supratentorial ganglioma: a positron emission tomography case report. Clin Nucl Med. 2000;25(9):694–7.
Franzius C, Sciuk J, Brinkschmidt C, et al. Evaluation of chemotherapy response in primary bone tumors with F-18 FDG positron emission tomography compared with histologically assessed tumor necrosis. Clin Nucl Med. 2000;25(11):874–81.
Carretta A, Landoni C, Melloni G, et al. 18-FDG positron emission tomography in the evaluation of malignant pleural diseases – a pilot study. Eur J Cardiothorac Surg. 2000;17(4):377–83.
Torre W, Garcia-Velloso MJ, Galbis J, et al. FDG-PET detection of primary lung cancer in a patient with an isolated cerebral metastasis. J Cardiovasc Surg. 2000;41(3):503–5.
Brunelle F. Noninvasive diagnosis of brain tumors in children. Childs Nerv Syst. 2000;16(10–11):731–4.
Mankoff DA, Dehdashti F, Shields AF. Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors. Neoplasia. 2000;2:71.
Fitzgerald J, Parker JA, Danias PG. F-18 fluorodeoxyglucose SPECT for assessment of myocardial viability. J Nucl Cardiol. 2000;7(4):382–7.
Schwarz A, Kuwert T. Nuclear medicine diagnosis in diseases of the central nervous system. Radiology. 2000;40(10):858–62.
Roelcke U, Leenders KL. PET in neuro-oncology. J Cancer Res Clin Oncol. 2001;127(1):2–8.
Brock CS, Meikle SR, Price P. Does 18F-fluorodeoxyglucose metabolic imaging of tumors benefit oncology? Eur J Nucl Med. 1997;24:691–705.
Syrota A, Comar D, Cerf M, et al. [11]C-methionine pancreatic scanning with positron emission computed tomography. J Nucl Med. 1979;20:778–81.
Syrota A, Duquesnoy N, Dasaf A, et al. The role of positron emission tomography in the detection of pancreatic disease. Radiology. 1982;143:249–53.
Kubota K, Yamada K, Fukuda H, et al. Tumor detection with carbon-11 labeled amino acid. Eur J Nucl Med. 1984;9:136–40.
Hagenfeldt L, Venizelos N, Bjerkenstedt L, et al. Decreased tyrosine transport in fibroblasts from schizophrenic patients. Life Sci. 1987;41:2749–57.
Tisljar U, Kloster G, Stocklin G. Accumulation of radioiodinated L-alpha-methyltyrosine in pancreas of mice: concise communication. J Nucl Med. 1979;20:973–6.
Kloss G, Leven M. Accumulation of radioiodinated tyrosine derivatives in the adrenal medulla and in melanomas. Eur J Nucl Med. 1979;4:179–86.
Langen KJ, Coenen HH, Roosen N, et al. SPECT studies of brain tumors with L-3-[123I]-Iodo-alpha-methyl tyrosine: comparison with PET, 124IMT and first clinical results. J Nucl Med. 1990;31:281–6.
Tomiyoshi K, Hirano T, Inoue T, et al. Positron emission tomography for evaluation of dopaminergic function using a neurotransmitter analog L-18F-m-tyrosine in monkey brain. Bioimages. 1996;4(1):1–7.
Wienhard K, Herholz K, Coenen HH, et al. Increased amino acid transport into brain tumors measured by PET of L-(2-18F)fluorotyrosine. J Nucl Med. 1991;32:1338–46.
Coenen HH, Kling P, Stocklin G, et al. Metabolism of L2-18F-fluorotyrosine, new PET tracer for protein synthesis. J Nucl Med. 1989;301:367–1372.
Ishiwata K, Valvurg W, Elsigna PH, et al. Metabolic studies with L-11C-tyrosine for the investigation of a kinetic model of measuring protein synthesis rate with PET. J Nucl Med. 1988;29:524–9.
Bolster JM, Valburg W, Paans AMJ, et al. Carbon-11 labeled tyrosine to study tumor metabolism by positron emission tomography (PET). Eur J Nucl Med. 1986;12:321–4.
Dejesus OT, Sunderland JJ, Nicles R, et al. Synthesis of radiofluorinated analogs of m-tyrosine as potential l-dopa tracers via direct reaction with acetylhypofluorite. Appl Radiat Isot. 1990;41(5):433–7.
Tang G, Wang M, Tang X, et al. Pharmacokinetics and radiation dosimetry estimation of O-(2-[18 F]fluoroethyl)-l-tyrosine as oncologic PET tracer. Appl Radiat Isot. 2003;58(2):219–25.
Hamacher K, Coenen HH. Efficient routine production of the 18F-labelled amino acid O-2-18F fluoroethyl-l-tyrosine. Appl Radiat Isot. 2002;57(6):853–6.
Rau FC, Weber WA, Wester HJ, et al. O-(2-[(18)F]Fluoroethyl)-l-tyrosine (FET): a tracer for differentiation of tumour from inflammation in murine lymph nodes. Eur J Nucl Med Mol Imaging. 2002;29(8):1039–46.
Fernandez MD, Burn JI, Sauven PD, et al. Activated estrogen receptors in breast cancer and response to endocrine therapy. Eur J Cancer Clin Oncol. 1984;20:41–6.
McGuire AH, Dehdashti F, Siegel BA, et al. Positron tomographic assessment of 16-alpha-[18F]fluoro-17-beta-estradiol uptake in metastatic breast carcinoma. J Nucl Med. 1991;32:1526–31.
McManaway ME, Jagoda EM, Kasid A, et al. [125I]17-beta-iodovinyl-11-beta-methoxyestradiol: interaction in vivo with ERS in hormone independent MCF-7 human breast cancer transfected with V-ras H oncogene. Cancer Res. 1987;47:2945–8.
Jagoda EM, Gibson RE, Goodgold H, et al. [125I]17-Iodovinyl-11-beta-methoxyestradiol: in vivo and in vitro properties of a high affinity estrogen-receptor radiopharmaceutical. J Nucl Med. 1984;25:472–7.
Hamm JT, Allegra JC. Hormonal therapy for cancer. In: Witts RE, editor. Manual of oncologic therapeutics. New York: Lippincott; 1991. p. 122–6.
Wittliff JL. Steroid-hormone receptor in breast cancer. Cancer Res. 1984;53:630–43.
Rasey JS, Nelson NJ, Chin L, et al. Characterization of the binding of labeled fluoromisonidazole in cells in vitro. Radiat Res. 1990;122:301–8.
Cherif A, Yang DJ, Tansey W, et al. Synthesis of [18F]fluoromisonidazole. Pharm Res. 1994;11:466–9.
Hwang DR, Dence CS, Bonasera TA, et al. No-carrier-added synthesis of 3-[18F]fluoro-1-(2-nitro-1-imidazolyl)-2-propanol. A potential PET agent for detecting hypoxic but viable tissues. Int J Radiat Appl Instrum A. 1989;40:117–26.
Jerabeck PA, Patrick TB, Kilbourn D, et al. Synthesis and biodistribution of 18F-labeled fluoronitroimidazoles: potential in vivo markers of hypoxic tissue. Appl Radiat Isot. 1986;37:599–605.
Parliament MB, Chapman JD, Urtasun RC, et al. Noninvasive assessment of tumor hypoxia with 123I-iodoazomycin arabinoside: preliminary report of a clinical study. Br J Cancer. 1992;65:90–5.
Valk PET, Mathis CA, Prados MD, et al. Hypoxia in human gliomas: demonstration by PET with [18F]fluoromisonidazole. J Nucl Med. 1992;33:2133–7.
Martin GV, Caldwell JH, Rasey JS, et al. Enhanced binding of the hypoxic cell marker [18F]fluoromisonidazole in ischemic myocardium. Nucl Med. 1989;30:194–201.
Martin GV, Cardwell JH, Graham MM, et al. Nonivasive detection of hypoxic myocardium using [18F]fluoromisonidazole and PET. J Nucl Med. 1992;33:2202–8.
Yeh SH, Liu RS, Hu HH, et al. Ischemic penumbra in acute stroke: demonstration by PET with fluorine-18 fluoromisonidazole. J Nucl Med. 1994;35(5):205. abst.
Yeh SH, Liu RS, Wu LC, et al. Fluorine-18 fluoromisonidazole tumour to muscle retention ratio for the detection of hypoxia in nasopharyngeal carcinoma. Eur J Nucl Med. 1996;23(10):1378–83.
Liu RS, Yeh SH, Chang CP, et al. Detection of odontogenic infections by [F-18]fluoromisonidazole. J Nucl Med. 1994;35(5):113. abst.
Yang DJ, Wallace S, Cherif A, et al. Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. Radiology. 1995;194:795–800.
Cherif A, Wallace S, Yang DJ, et al. Development of new markers for hypoxic cells: [131I]iodomisonidazole and [131I]iodoerythronitroimidazole. J Drug Target. 1996;4(1):31–9.
Inoue T, Yang DJ, Wallace S, et al. Evaluation of [131I]iodoerythronitroimidazole as a predictor for the radiosensitizing effect. Anticancer Drugs. 1996;7(8):858–65.
Podo F. Tumor phospholipid metabolism. NMR Biomed. 1999;12:413–39.
Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med. 1998;39:990–5.
Hara T, Kosaka N, Shinoura N, et al. PET imaging of brain tumor with [methyl-11C]choline. J Nucl Med. 1997;38:842–7.
Hara T, Kosaka N, Kishi H, et al. Imaging of brain tumor, lung cancer, esophagus cancer, colon cancer, prostate cancer, and bladder cancer with [C-11]choline. J Nucl Med. 1997;38:250P.
Kotzerke J, Prang J, Neumaier B, et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med. 2000;27:1415–9.
DeGrado TR, Baldwin SW, Wang S, et al. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med. 2001;42(12):1805–14.
Price DT, Coleman RE, Liao RP, et al. Comparison of [18F]fluorocholine and [18F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol. 2002;168(1):273–80.
DeGrado TR, Reiman RE, Price DT, et al. Pharmacokinetics and radiation dosimetry of 18 F-fluorocholine. J Nucl Med. 2002;43(1):92–6.
Haberkorn U, Khazaie K, Morr I, et al. Ganciclovir uptake in human mammary carcinoma cells expressing herpes simplex virus thymidine kinase. Nucl Med Biol. 1998;25:367–73.
Gambhir SS, Barrio JR, Wu L, et al. Imaging of adenoviral-directed herpes simplex virus type 1 thymidine kinase reporter gene expression in mice with radiolabeled ganciclovir. J Nucl Med. 1998;39:2003–11.
Gambhir SS, Barrio JR, Phelps ME, et al. Imaging adenoviral-directed reporter gene expression in living animals with positron emission tomography. Proc Natl Acad Sci USA. 1999;96:2333–8.
Namavari M, Barrio JR, Toyokuni T, et al. Synthesis of 8-[18F]fluoroguanine derivatives: in vivo probes for imaging gene expression with positron emission tomography. Nucl Med Biol. 2000;27:157–62.
Gambhir SS, Bauer E, Black ME, et al. A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography. Proc Natl Acad Sci USA. 2000;97:2785–90.
Iyer M, Barrio JR, Namavari M, et al. 8-[18F]Fluoropenciclovir: an improved reporter probe for imaging HSV1-tk reporter gene expression in vivo using PET. J Nucl Med. 2001;42:96–105.
Alauddin MM, Conti PS, Mazza SM, et al. 9-[(3-[18F]-Fluoro-1-hydroxy-2-propoxy)methyl]guanine ([18F]-FHPG): a potential imaging agent of viral infection and gene therapy using PET. Nucl Med Biol. 1996;23:787–92.
Alauddin MM, Shahinian A, Kundu RK, et al. Evaluation of 9-[(3-18F- fluoro-1-hydroxy-2-propoxy)methyl]guanine ([18F]-FHPG) in vitro and in vivo as a probe for PET imaging of gene incorporation and expression in tumors. Nucl Med Biol. 1999;26:371–6.
Alauddin MM, Conti PS. Synthesis and preliminary evaluation of 9-(4-[18F]-fluoro-3-hydroxymethylbutyl)guanine ([18F]FHBG): a new potential imaging agent for viral infection and gene therapy using PET. Nucl Med Biol. 1998;25:175–80.
Yaghoubi S, Barrio JR, Dahlbom M, et al. Human pharmacokinetic and dosimetry studies of [18F]FHBG: a reporter probe for imaging herpes simplex virus type-1 thymidine kinase reporter gene expression. J Nucl Med. 2001;42:1225–34.
Yang DJ, Cherif A, Tansey W, et al. N, N-diethylfluoromethyltamoxifen: synthesis assignment of 1H and 13C spectra and receptor assay. Eur J Med Chem. 1992;27:919–24.
Yang D, Tewson T, Tansey W, et al. Halogenated analogs of tamoxifen: synthesis, receptor assay and inhibition of MCF7 cells. J Pharm Sci. 1992;81: 622–5.
Kim CG, Yang DJ, Kim EE, et al. Assessment of tumor cell proliferation using [18F]fluorode-oxyadenosine and [18F]fluoroethyluracil. J Pharm Sci. 1996;85(3):339–44.
Cherif A, Yang DJ, Tansey W, et al. Radiosynthesis and biodistribution studies of [F-18]fluoroadenosine and [I-131]-5-iodo-2′-O-methyl-uridine for the assessment of tumor proliferation rate. Pharm Res. 1995;12(9):128.
Yang D, Wallace S. High affinity tamoxifen derivatives and uses thereof. U.S. Patent no 5,192,525; 1993.
Yang D, Wallace S, Wright KC, et al. Imaging of estrogen receptors with PET using 18F-fluoro analogue of tamoxifen. Radiology. 1992;182:185–6.
Yang DJ, Kuang L-R, Cherif A, et al. Synthesis of 18F-alanine and 18F-tamoxifen for breast tumor imaging. J Drug Target. 1993;1:259–67.
Yang DJ, Li C, Kuang L-R, et al. Imaging, biodistribution and therapy potential of halogenated tamoxifen analogues. Life Sci. 1994;55(1):53–67.
Yang DJ, Wallace S. High affinity halogenated tamoxifen derivatives and uses thereof. U.S. Patent no 5,219,548; 1993.
Inoue T, Kim EE, Wallace S, et al. Positron emission tomography using [18F]fluorotamoxifen to evaluate therapeutic responses in patients with breast cancer: preliminary study. Cancer Biother Radiopharm. 1996;11(4):235–45.
Inoue T, Kim EE, Wallace S, et al. Preliminary study of cardiac accumulation of F-18 fluorotamoxifen in patients with breast cancer. Clin Imaging. 1997;21(5):332–6.
Hanson RN, Seitz DE. Tissue distribution of the radiolabeled antiestrogen [125I]iodotamoxifen. Int J Nucl Med Biol. 1982;9:105–7.
Ram S, Spicer LD. Radioiodination of tamoxifen. J Label Compd Radiopharm. 1989;27:661–8.
Kangas L, Nieminen A-L, Blanco G, et al. A new triphenylethylene, FC-1157a, antitumor effects. Cancer Chemother Pharmacol. 1986;17:109–13.
Kallio S, Kangas L, Blanco G, et al. A new triphenylethylene, FC-1157a, hormonal effects. Cancer Chemother Pharmacol. 1986;17:103–8.
Kawai G, Yamamoto Y, Kamimura T, et al. Conformational rigidity of specific pyrimidine residues in tRNA arises from posttranscriptional modifications that enhance steric interaction between the base and the 2′-hydroxyl group. Biochemistry. 1992;31:1040–5.
Uesugi S, Kaneyasu T, Ikehara M. Synthesis and properties of ApU analogues containing 2′-halo-2′-deoxyadenosine. Effect of 2′ substituents on oligonucleotide conformation. Biochemistry. 1982;21: 5870–7.
Ikehara M, Miki H. Studies of nucleosides and nucleotides. Cyclonucleosides. Synthesis and properties of 2′-halogeno-2′-deoxyadenosines. Chem Pharm Bull. 1978;26:2449–53.
Inubushi M, Wu JC, Gambhir SS, et al. Positron-emission tomography reporter gene expression imaging in rat myocardium. Circulation. 2003;107(2):326–32.
Tjuvajev JG, Doubrovin M, Akhurst T, et al. Comparison of radiolabeled nucleoside probes (FIAU, FHBG, and FHPG) for PET imaging of HSV1-tk gene expression. J Nucl Med. 2002;43(8): 1072–83.
Acknowledgments
The animal research reported here is supported by a Cancer Center Core grant, NIH-NCI CA-16672.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Yang, D.J., Inoue, T., Kim, E.E. (2013). Radiopharmaceuticals. In: Kim, E., Lee, MC., Inoue, T., Wong, WH. (eds) Clinical PET and PET/CT. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0802-5_4
Download citation
DOI: https://doi.org/10.1007/978-1-4419-0802-5_4
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-0801-8
Online ISBN: 978-1-4419-0802-5
eBook Packages: MedicineMedicine (R0)